Drug intelligence / Profile preview

HR2301

Development stage: Unknown
Lead developer: Nanjing Heron Pharmaceutical Science & Technology
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

HR2301 is a small molecule analgesic being developed by Nanjing Heron Pharmaceutical for the treatment of moderate-to-severe pain. Classified as a Class 1 innovative drug (New Chemical Entity) in China, it is designed for both oral and intravenous (IV) administration. The drug is part of Heron Pharmaceutical's core R&D focus on the analgesia field, aiming to provide a potent therapeutic option for acute and chronic pain management. It has received Investigational New Drug (IND) approval from the NMPA and has progressed into clinical trials.

Beyond the preview

Go deeper on HR2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR2301.

Explore the full profile